Results 171 to 180 of about 14,613 (227)
Drug Safety, 2012 Flecainide is a class Ic antiarrhythmic agent that has an important role as part of rhythm control strategies in patients with atrial fibrillation (AF). Early clinical data on the use of flecainide showed an increase in arrhythmias and mortality compared with placebo in patients with a previous myocardial infarction and asymptomatic or mildly ...
Tamargo, Juan +2 more
openaire +3 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Flecainide How and When: A Practical Guide in Supraventricular Arrhythmias
Journal of Clinical Medicine, 2021 Transcatheter ablation was increasingly and successfully used to treat symptomatic drug refractory patients affected by supraventricular arrhythmias. Antiarrhythmic drug treatment still plays a major role in patient management, alone or combined with non-
Michele Magnocavallo
exaly +2 more sources
Flecainide in Ventricular Arrhythmias: From Old Myths to New Perspectives
Journal of Clinical Medicine, 2021 Flecainide is an IC antiarrhythmic drug (AAD) that received in 1984 Food and Drug Administration approval for the treatment of sustained ventricular tachycardia (VT) and subsequently for rhythm control of atrial fibrillation (AF).
Michele Magnocavallo
exaly +2 more sources
Flecainide: evidence of non-linear kinetics
European Journal of Clinical Pharmacology, 1991 The pharmacokinetics of flecainide has been studied in 12 patients with ventricular arrhythmias, both after single administration and during chronic treatment. Both the half-life and the AUC were significantly increased during chronic treatment.
A Capucci, B Magnani
exaly +2 more sources
Journal of Cardiovascular Electrophysiology, 1994
Flecainide. Flecainide is a Class IC antiarrhythmic agent whose primary electrophysiologic effect is a slowing of conduction in a wide range of cardiac tissues. It is well absorbed and effective in suppressing isolated premature ventricular contractions (PVCs) or nonsustained ventricular arrhythmia but has only a modest efficacy when electrophysiologic
R H, Falk, R I, Fogel
openaire +2 more sources
Flecainide. Flecainide is a Class IC antiarrhythmic agent whose primary electrophysiologic effect is a slowing of conduction in a wide range of cardiac tissues. It is well absorbed and effective in suppressing isolated premature ventricular contractions (PVCs) or nonsustained ventricular arrhythmia but has only a modest efficacy when electrophysiologic
R H, Falk, R I, Fogel
openaire +2 more sources
American Heart Journal, 2021
BACKGROUND Class 1C antiarrhythmic drugs(AAD) have been associated with harm in patients treated for ventricular arrhythmias with a prior myocardial infarction(MI).
Tyson S Burnham +13 more
semanticscholar +1 more source
BACKGROUND Class 1C antiarrhythmic drugs(AAD) have been associated with harm in patients treated for ventricular arrhythmias with a prior myocardial infarction(MI).
Tyson S Burnham +13 more
semanticscholar +1 more source
European Heart Journal, 1987
Flecainide and encainide (class IC) are presently under clinical evaluation in Italy. They prolong the duration of the QRS but not the period of ventricular repolarisation: the prolongation of QT is due solely to the prolongation of the Q-J.
F, Furlanello +5 more
openaire +2 more sources
Flecainide and encainide (class IC) are presently under clinical evaluation in Italy. They prolong the duration of the QRS but not the period of ventricular repolarisation: the prolongation of QT is due solely to the prolongation of the Q-J.
F, Furlanello +5 more
openaire +2 more sources
The American Journal of Cardiology, 1984
After oral administration in healthy human subjects, flecainide absorption is prompt (average peak level at 3 to 4 hours) and nearly complete (at least 90%); flecainide does not appear to undergo consequential presystemic biotransformation. Oral absorption in patients with cardiac arrhythmias, renal disease and congestive heart failure (CHF) is also ...
G J, Conard, R E, Ober
openaire +2 more sources
After oral administration in healthy human subjects, flecainide absorption is prompt (average peak level at 3 to 4 hours) and nearly complete (at least 90%); flecainide does not appear to undergo consequential presystemic biotransformation. Oral absorption in patients with cardiac arrhythmias, renal disease and congestive heart failure (CHF) is also ...
G J, Conard, R E, Ober
openaire +2 more sources